CASH IS KING RIGHT NOW – Keeping the watchlist short and tight, so here is an overview:
HOT SECTORS:
-
School, College & University ^VTRU ^LXEH
-
Uranium ^NXE ^CCJ
-
Natural Gas ^AFYA ^COE ^FC ^ARCE
-
Professional &Business Education ^MGY ^PNRG ^XEC
-
Textiles & Apparel ^GIL ^RCKY ^CULP ^FOSL
-
Pharmaceuticals ^CELG-RT ^ANIK ^PETQ
AH RUNNERS TURN POTENTIAL PM GAPPERS: $STRS $AFI $CREX $TMST $SEM $ICCC $GRPN
SHORT PLAYS (ALL GETTING LOT OF BUYS TONIGHT): $SQQQ $SDOW $SCO $QID $TWM $SPXU $PSQ $TZA
VIX PLAYS: $UVXY $VXX $VIXY $TVIXF
OIL & GAS:
$FTI – UP 12% on a terribly red day. Why? The company anticipates that growth in international activity will fuel full-year revenue growth in its surface technologies segment. Meanwhile, it expects to book more than $4 billion of orders within its subsea technologies group, which should support solid results in that segment and more order growth in 2022. Longer term, the company believes it's well-positioned for the energy transition to cleaner fuel sources, noting it sees significant opportunities in subsea, including wind, wave energy, carbon storage, and green hydrogen. This is a fundamentally sound company, and it looks like that’s what was moving today with all of the speculation plays dying down.
$HUSA – Daily Chart looks strong with a golden cross, pullback to sling shot and buy arrow printed. Beautiful dip here as if the month never happened.
Sympathy/Related: #PHX #BPT #PRT #KOS #KRP #EQNR #WTI
BIOTECH/HEALTHCARE:
$MESO – Back on 2/17, MESO was the recipient of a Pediatrics Journal Entry which documented the success of Mesoblast’s mesenchymal stromal cell product candidate remestemcel-L for multisystem inflammatory syndrome associated with COVID-19. There were no safety signals and both patients treated were discharged from the hospital. Tonight, MESO was halted until March 2 for upcoming news pending. My guess? This therapy was just awarded an emergency approval by the FDA to treat COVID-19 in children. This news would send shock waves through the market as schools would have a new therapy to treat and cure children should they become infected.
$PAND - Pandion, a clinical-stage biotech that targets autoimmune and inflammatory ailments, is being bought out by global pharmaceutical giant Merck. The deal's total equity value is roughly $1.85 billion; under the terms of the agreement between the two companies, Merck will pay $60 per share in cash for the acquisition, which is more than double Pandion's closing stock price on Wednesday. Stock ran to EXACTLY $60 a share by the close of after hours.
$CDXC - ChromaDex Corp. today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
Sympathy/Related: #ASLN #ABEO #RVPH #ALGS #BLUE #PHVS #ALXO #PSTX #AKUS #CGIX
EARNINGS:
$CNK- Cinemark Holdings & $AMC – AMC Entertainment
Back Burners: ^PETZ ^WKHS ^GME ^KOSS ^NAKD ^JAN ^SCKT ^BB ^BBBY ^NOK ^KIQ ^TMBR ^GTT
